SAQ 1 — Classification and the governance pathway

Stem (20 marks; suggested 15 minutes): [6]

A 3-month-old infant is started on propranolol oral solution for a proliferating infantile haemangioma. The propranolol product is licensed for hypertension in adults. Separately, the neonatal unit where you work prepares a caffeine citrate solution in the hospital pharmacy because no licensed preparation exists at the required strength for preterm infants. [6] [5]

(a) Define licensed, off-label and unlicensed medicine use, and classify each of the two scenarios above into one of these categories. (8 marks) [1]

(b) Outline the stepwise governance pathway a prescriber should follow when a medicine is needed outside its licence. (8 marks) [7]

(c) State the pharmacovigilance duty that applies when a child on an off-label or unlicensed medicine has a suspected adverse drug reaction, and name one national reporting scheme. (4 marks) [8]

Model answer — SAQ 1

(a) Definitions and classification (8 marks). [1]

• Licensed (on-label) use — a medicine used within all the terms of its marketing authorisation: the approved age or weight band, indication, route, dose and formulation. (1 mark)
• Off-label use — a licensed product used outside one or more of those terms (different age or weight, indication, route, dose, or formulation). (1 mark)
• Unlicensed use — a medicine with no valid marketing authorisation for that product or formulation in the jurisdiction: specials, imported products, extemporaneous compounding, or an investigational product. (1 mark)
• Propranolol for the infantile haemangioma is off-label: the product is licensed (for adult hypertension) but used outside the licensed age, indication and dose. (2 marks — must name the licensed-product-outside-a-term reasoning)
• The pharmacy-prepared caffeine citrate is unlicensed: no marketing authorisation exists for that formulation; it is compounded because no licensed preparation is available at the required strength. (2 marks — must name the no-licence-for-the-formulation reasoning)
• Make explicit that both are legal, common and often evidence-based — they are prescribing categories, not errors. (Concept-recognition mark embedded above; do not award if the candidate conflates off-label with unlicensed or with error.) [1] [6]

(b) Governance pathway (8 marks — 1 mark per named step, capped at 8). [7]

1. Check whether a licensed alternative that meets the clinical need exists and is locally available; if so, prefer it. [7]
2. Confirm the evidence base for the proposed off-label or unlicensed use — a guideline, systematic review or formulary monograph. If the evidence is thin, seek alternatives or specialist/Medicines Committee advice. [6]
3. Choose the safest formulation — prefer a licensed product used off-label over an unlicensed compounded or imported product where possible; confirm stability and strength with pharmacy. [5]
4. Document the indication, evidence base, weight-based dose (child weighed in kilograms), family discussion and local approval status. [7]
5. Counsel the family and obtain consent (and assent where the child is competent); explain the medicine is off-label and why it is the best choice. [7]
6. Monitor efficacy and adverse drug reactions; intensify monitoring where the dose is uncertain. [8]
7. Report suspected adverse drug reactions to the national pharmacovigilance scheme. [8]
8. For high-risk off-label or unlicensed use (narrow therapeutic index, neonate, IV inotrope/sedative, compounded formulation), obtain senior sign-off and notify the local Medicines Committee before the first dose. [7]

(c) Pharmacovigilance duty (4 marks). [8]

• Off-label and unlicensed medicines are associated with a higher rate of adverse drug reactions (Bellis 2013), and the post-marketing database for these uses is thin, so every suspected reaction should be reported. (2 marks)
• Reporting is on suspicion, not proof. (1 mark)
• Name one national scheme: the Yellow Card (UK), the Blue Card / ADRS scheme (Australia), or MedWatch (US). (1 mark) [8] [4]

SAQ 2 — The evidence gap and the regional regulatory response

Stem (20 marks; suggested 15 minutes): [6]

A fellowship examiner asks: "Why is so much paediatric prescribing outside the product licence, and what have regional regulators done about it?" [1] [6]

(a) Explain the structural reasons why off-label and unlicensed medicine use is common in children. (10 marks) [6]

(b) Describe the regulatory mechanisms introduced in the European Union and the United States to close the paediatric evidence gap, and summarise the evidence on whether they have reduced off-label use. (10 marks) [10]

Model answer — SAQ 2

(a) Structural reasons (10 marks — drivers, each with a brief mechanism). [6]

• The market gap — children are a small, fragmented market split across age bands, so the commercial return on a paediatric programme is low and the perceived medicolegal risk is high. (2 marks)
• Trial logistics — paediatric trials need parental consent and child assent, age-stratified cohorts, and relatively larger blood volumes per sample, making them slower and costlier. (2 marks)
• Developmental pharmacokinetics — absorption, distribution, metabolism and excretion change with gestational and postnatal age, so adult pharmacology cannot be linearly scaled to children. (2 marks)
• The formulation gap — many drugs have no age-appropriate, palatable, strength-correct paediatric formulation, forcing crushed tablets, split doses or pharmacy-made solutions. (2 marks)
• Regulatory lag — medicines are licensed for adults first, and the paediatric licence, if it comes at all, follows years later. (2 marks)
• Recognise that these five drivers converge on a single paediatric evidence gap — no licensed age, indication, dose or formulation for the child in front of you. (Synthesis mark embedded above.) [6] [1]

(b) Regulatory response and effect (10 marks). [10]

• European Union: the EU Paediatric Regulation (in force 2007) requires companies to submit a Paediatric Investigation Plan (PIP) describing the paediatric studies and age-appropriate formulations needed, and it created rewards for generating paediatric data. (3 marks) [10]
• United States: the Best Pharmaceuticals for Children Act (BPCA) offers paediatric exclusivity in exchange for FDA-requested paediatric studies, and the Pediatric Research Equity Act (PREA) requires paediatric assessment of certain new drugs; together, made permanent under the FDASIA framework, they have generated many paediatric label changes. (3 marks) [7]
• Effect: Lindell-Osuagwu's 2014 before-and-after study found the EU Regulation increased the volume of paediatric data but had not yet translated into a clear fall in off-label and unlicensed prescribing at the ward level; Nir-Neuman (2018) showed NICU/PICU prevalence essentially unchanged over a decade. (3 marks) [10] [9]
• Synthesis: the frameworks are necessary but not sufficient — they generate data, but the data take time to reach the bedside, so bedside reporting and local governance still do the heavy lifting. (1 mark) [10] [8]